Personal information

Clinical Development, Cardiovascular, Infectious Disease, SARS-CoV-2
United States

Activities

Works (4)

Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial

The Lancet Infectious Diseases
2024-09 | Journal article
Part of ISSN: 1473-3099
Contributors: Flonza Isa; Ana M Gonzalez Ortiz; Jonathan Meyer; Jennifer D Hamilton; Benjamin A Olenchock; Taylor Brackin; Samit Ganguly; Eduardo Forleo-Neto; Lori Faria; Ingeborg Heirman et al.
Source: Self-asserted source
Jonathan Aaron Meyer

Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone

Nature
2024-09-19 | Journal article
Contributors: Michael E. Dunn; Aaron Kithcart; Jee Hae Kim; Andre Jo-Hao Ho; Matthew C. Franklin; Annabel Romero Hernandez; Jan de Hoon; Wouter Botermans; Jonathan Meyer; Ximei Jin et al.
Source: check_circle
Crossref

A novel agonist antibody to membrane-bound guanylate cyclase receptor, natriuretic peptide receptor 1, induces sustained vasodilation

2023-04-26 | Preprint
Contributors: Michael Dunn; Aaron Kithcart; Jee Hae Kim; Andre Jo-Hao Ho; Matthew Franklin; Annabel Romero Hernandez; Jan de Hoon; Wouter Botermans; Jonathan Meyer; Ximei Jin et al.
Source: check_circle
Crossref

Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

International Journal of Infectious Diseases
2022-09 | Journal article
Contributors: Flonza Isa; Eduardo Forleo-Neto; Jonathan Meyer; Wenjun Zheng; Scott Rasmussen; Danielle Armas; Masaru Oshita; Cynthia Brinson; Steven Folkerth; Lori Faria et al.
Source: check_circle
Crossref